Wall Street Top Analysts' Latest Ratings: Uber Upgraded

Wall Street's most closely watched research ratings that can influence market movements have been compiled. Below are the key analyst rating changes investors should focus on today.

Five Companies with Upgraded Ratings:

Arete upgraded Uber Uber (UBER) from "Neutral" to "Buy," raising its price target from $82 to $125. The firm believes investor concerns about autonomous vehicle competition are overblown.

Arete also upgraded Lyft (LYFT) from "Sell" to "Neutral," increasing its price target from $10 to $20. The firm noted that while Lyft currently has fewer autonomous vehicle partnerships than Uber, it could potentially collaborate with Amazon's (AMZN) Zoox by 2026.

Longbow upgraded Garmin (GRMN) from "Neutral" to "Buy" with a $250 price target. The firm stated that Garmin's recent 25% stock decline was an overreaction to concerns about potential automotive revenue shortfalls in early 2026 affecting full-year growth.

Morgan Stanley upgraded Vertex Pharmaceuticals (VRTX) from "Equal-Weight" to "Overweight," raising its price target from $438 to $516. The firm expressed increased optimism about the company's kidney disease drug pipeline, including Pove and Inaxaplin.

William Blair upgraded Driven Brands (DRVN) from "Market Perform" to "Outperform" without specifying a price target. The upgrade followed meetings with management, which indicated that new leadership was demonstrating strength after years of executive turnover.

Five Companies with Downgraded Ratings:

Jefferies downgraded Wayfair (W) from "Buy" to "Hold," maintaining its $94 price target. The firm cited slow holiday season website traffic and declining consumer purchase intent as reasons for the more cautious stance.

JPMorgan downgraded Wendy's (WEN) from "Overweight" to "Neutral," lowering its price target from $12 to $9. The bank adopted a wait-and-see approach pending clearer strategic direction from permanent management.

Susquehanna downgraded Pure Storage (PSTG) from "Positive" to "Neutral," keeping its $100 price target. While concerns about margins have eased, the firm noted that hyperscale customer revenue growth would be slower than expected.

Morgan Stanley downgraded Regeneron Pharmaceuticals (REGN) from "Overweight" to "Equal-Weight," maintaining its $767 price target. The firm sees balanced risk/reward until the company's drug pipeline diversification becomes clearer.

Citizens JMP downgraded Jamf Holding (JAMF) from "Outperform" to "Market Perform" without specifying a price target, following the company's announcement of its acquisition by Francisco Partners at $13.05 per share.

Five Companies Receiving Initial Coverage:

Wells Fargo initiated coverage on Oracle (ORCL) with an "Overweight" rating and $280 price target, citing the company's potential leadership in the AI "super cycle."

UBS started coverage on Roblox (RBLX) with a "Neutral" rating and $103 price target. While platform improvements may drive user growth and spending, the firm expects slower growth in 2026 as blockbuster product effects fade and investment needs increase.

Barclays resumed coverage on Capri Holdings (CPRI) with an "Overweight" rating and $31 price target, citing improved promotional activity, Michael Kors' momentum, and the successful Versace sale.

UBS initiated coverage on Casey's General Stores (CASY) with a "Neutral" rating and $600 price target, expecting market share gains but remaining cautious about near-term challenges and valuation.

Citizens JMP started coverage on Zymeworks (ZYME) with an "Outperform" rating and $32 price target, highlighting FDA approval for its first internally developed drug candidate, zanidatamab.